{"entity":{"id":"nct07288112","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","aka":[],"tldr":"A phase 1/2 trial of DOC1021 in melanoma, run by Diakonos Oncology Corporation, now recruiting.","summary":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma is a phase 1/2 interventional study registered as NCT07288112 by Diakonos Oncology Corporation, with 35 participants planned, started 2026-04-06 and due to reach its primary completion in 2031-01. Interventions recorded: DOC1021, Tumor resection and pIFN (peginterferon alfa-2a).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07288112","url":"https://clinicaltrials.gov/study/NCT07288112"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["diakonos-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07288112","phase":"1/2","setting":"Clinical Study of DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","sponsor":"Diakonos Oncology Corporation","enrolled":35,"outcomes":[]},"route":"/trials/nct07288112/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"company":[{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","route":"/companies/diakonos-oncology/"}],"drug":[{"id":"doc1021","kind":"drug","name":"DOC1021","route":"/drugs/doc1021/"}]}}